CD274 and non-small cell lung carcinoma: In another trial, KEYNOTE-598, enrolling a similar patient population (metastatic NSCLC, PD-L1 TPS ≥50%, no EGFR/ALK alterations), patients who received first-line pembrolizumab monotherapy experienced median OS of 21.9 months (4).